Transcriptional Regulation of the Intestinal Nuclear Bile Acid Farnesoid X Receptor (FXR) by the caudal-related Homeobox 2 (CDX2)

Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions

(2013) Felipe De Sousa E Melo et al.   NATURE MEDICINE

Cdx2 determines the fate of postnatal intestinal endoderm

(2011) E. J. Stringer et al.   DEVELOPMENT

Cdx2 Controls Expression of the Protocadherin Mucdhl, an Inhibitor of Growth and β-Catenin Activity in Colon Cancer Cells

(2011) Isabelle Hinkel et al.   GASTROENTEROLOGY

Bile acids and colon cancer: Solving the puzzle with nuclear receptors

(2011) Chiara Degirolamo et al.   TRENDS IN MOLECULAR MEDICINE

Differentiation-Specific Histone Modifications Reveal Dynamic Chromatin Interactions and Partners for the Intestinal Transcription Factor CDX2

(2010) Michael P. Verzi et al.   DEVELOPMENTAL CELL

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer

(2009) Y. Baba et al.   CLINICAL CANCER RESEARCH

Establishment of Intestinal Identity and Epithelial-Mesenchymal Signaling by Cdx2

(2009) Nan Gao et al.   DEVELOPMENTAL CELL

Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio

(2009) Salvatore Modica   Frontiers in Bioscience-Landmark

The Intestinal Nuclear Receptor Signature With Epithelial Localization Patterns and Expression Modulation in Tumors

(2009) Salvatore Modica et al.   GASTROENTEROLOGY

Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis

(2008) S. Modica et al.   CANCER RESEARCH

Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development

(2008) R. R.M. Maran et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS